What is Acrux Limited (ARUXF)?

Acrux Limited (ARUXF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ARUXF?

The current price of ARUXF is $0.00. Prices are updated in real time on Stocks360.

What is ARUXF's price-to-earnings (PE) ratio?

ARUXF's trailing twelve-month PE ratio is -7.14, based on current price and earnings per share data available on Stocks360.

What is ARUXF's market capitalization?

ARUXF's market capitalization is $40,143.00, placing it in the small-cap tier.

Acrux Limited (ARUXF)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$40.14K

PE (TTM)

-7.14

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.97

Day Range

$0.00 – $0.02

52-wk Range

$0.00 – $0.05

Avg Volume

N/A

Volume

40.00K

Acrux Limited (ARUXF) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $40.14K. Trailing PE -7.14. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $0.03 2026-10-26 · $0.00 (-99.67%)

Earnings

Next Earnings

Mar 2, 2027

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Acrux Limited

Acrux Limited, alongside its affiliated entities, specializes in the global development and commercialization of generic and topical pharmaceutical products. The company's reach extends across international markets, including Australia, Europe, and the United States. A significant part of its offerings includes diverse testosterone therapies, available in various forms such as oral and buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels, all aimed at treating adult men with low or absent testosterone levels. Additionally, Acrux provides estradiol sprays, sold under the brand names Evamist and Lenzetto, specifically formulated for women experiencing hot flashes associated with menopause. The company, established in 1998, is headquartered in West Melbourne, Australia.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-7.14×
P/S (TTM)	1.32×
P/B	2.86×
P/FCF (TTM)	4.98×
EV / EBITDA	-4.08×
EV / Sales	1.49×
Earnings Yield	-14.38%
Free Cash Flow Yield	20.08%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$6.93M
Revenue (TTM)	$4.64M
Net Income (TTM)	-$880.00K
Free Cash Flow (TTM)	$1.30M
Net Debt	$813.00K
Working Capital	$1.11M
Gross Margin	90.57%
Operating Margin	-46.06%
Net Margin	-13.01%
Return on Equity	-45.29%
Return on Invested Capital	-10.70%